NCT07482228 Long-term Clinical Outcomes After Retinal Artery Occlusion
| NCT ID | NCT07482228 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Chonnam National University Hospital |
| Condition | Retinal Artery Occlusion |
| Study Type | OBSERVATIONAL |
| Enrollment | 15,000 participants |
| Start Date | 2026-03-01 |
| Primary Completion | 2026-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 15,000 participants in total. It began in 2026-03-01 with a primary completion date of 2026-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Retinal artery occlusion (RAO) is a rare but vision-threatening vascular disorder that is commonly caused by embolic events originating from the heart or carotid arteries. Patients with RAO are known to have an increased risk of subsequent cardiovascular and cerebrovascular events, including ischemic stroke and myocardial infarction. However, long-term outcomes and optimal medical treatment strategies for these patients remain insufficiently characterized. The purpose of this nationwide population-based study is to investigate the incidence of long-term cardiovascular and cerebrovascular outcomes in patients diagnosed with retinal artery occlusion using the Korean National Health Insurance Service (NHIS) database. In addition, the study aims to evaluate the impact of various medical therapies, including antiplatelet agents, anticoagulants, and statins, on long-term clinical outcomes.
Eligibility Criteria
Inclusion Criteria: * Patients newly diagnosed with retinal artery occlusion Exclusion Criteria: * Patients with a prior diagnosis of retinal artery occlusion before the study period. * Patients diagnosed with giant cell arteritis.
Contact & Investigator
Seung Hun Lee, MD, PhD
PRINCIPAL INVESTIGATOR
Chonnam National University Hospital
Frequently Asked Questions
Who can join the NCT07482228 clinical trial?
This trial is open to participants of all sexes, studying Retinal Artery Occlusion. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07482228 currently recruiting?
Yes, NCT07482228 is actively recruiting participants. Contact the research team at lsh8602@naver.com for enrollment information.
Where is the NCT07482228 trial being conducted?
This trial is being conducted at Gwangju, South Korea.
Who is sponsoring the NCT07482228 clinical trial?
NCT07482228 is sponsored by Chonnam National University Hospital. The principal investigator is Seung Hun Lee, MD, PhD at Chonnam National University Hospital. The trial plans to enroll 15,000 participants.